Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity
Lekha Mikkilineni, James N. Kochenderfer(National Institutes of Health), Elisabet E. Manasanch(National Institutes of Health), Tyler Lowe(National Institutes of Health), Jennifer N. Brudno(National Institutes of Health), Micaela Ganadan(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Steven A. Rosenberg(National Cancer Institute), David F. Stroncek(Yale University), Norris Lam(National Institutes of Health), Jennifer Mann(National Institutes of Health), Stephanie L. Goff(Unknown), Rashmika Patel(National Institutes of Health), Danielle Natrakul(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), James C. Yang(National Taiwan University Hospital), Steven L. Highfill(National Institutes of Health), Irina Marić(Center for Cancer Research), Constance M. Yuan(National Cancer Institute)
Cited by 9
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
|Journal of Clinical Oncology|2008|1.3k
IL-2: The First Effective Immunotherapy for Human Cancer
|The Journal of Immunology|2014|1.3k